Literature DB >> 18720000

The simultaneous expression of peroxisome proliferator-activated receptor delta and cyclooxygenase-2 may enhance angiogenesis and tumor venous invasion in tissues of colorectal cancers.

Masahiro Yoshinaga1, Yosuke Kitamura, Tomohito Chaen, Shinsaku Yamashita, Satoru Tsuruta, Teruaki Hisano, Yoichi Ikeda, Hironori Sakai, Kazuhiko Nakamura, Ryoichi Takayanagi, Yoichi Muto.   

Abstract

We conducted this study to evaluate the impact of the expression of peroxisome proliferator-activated receptor delta on angiogenesis in tissue samples of colorectal cancer. We examined 52 samples of primary human colorectal carcinomas and matched normal adjacent tissues to evaluate the expression of peroxisome proliferator-activated receptor delta, cyclooxygenase-2, vascular endothelial growth factor-A, and CD34 through immunohistochemical analysis. Peroxisome proliferator-activated receptor delta was expressed in 25 (48.1%), and cyclooxygenase-2 was expressed in 26 (50.0%) of total colorectal cancer tissues. Tissue samples were divided into four groups, according to the expression of peroxisome proliferator-activated receptor delta and cyclooxygenase-2. The positive rate of vascular endothelial growth factor-A, the levels of microvascular density, and the incidence of venous vessel invasion in peroxisome proliferator-activated receptor delta (+)/cyclooxygenase-2 (+) samples exceeded significantly those in the other three groups of tissue samples (P<0.05). The results suggest that the axis of the cyclooxygenase-2/peroxisome proliferator-activated receptor delta signal pathway might play a crucial role in the development of colorectal cancers by enhancing angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18720000     DOI: 10.1007/s10620-008-0465-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  36 in total

Review 1.  The PPARs: from orphan receptors to drug discovery.

Authors:  T M Willson; P J Brown; D D Sternbach; B R Henke
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

Review 2.  The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways.

Authors:  S A Kliewer; J M Lehmann; M V Milburn; T M Willson
Journal:  Recent Prog Horm Res       Date:  1999

3.  Prognostic values of tumor endothelial markers in patients with colorectal cancer.

Authors:  K A Rmali; M C A Puntis; W G Jiang
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

4.  Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas.

Authors:  M F Acikalin; U Oner; I Topçu; B Yaşar; H Kiper; E Colak
Journal:  Dig Liver Dis       Date:  2004-12-09       Impact factor: 4.088

5.  Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells.

Authors:  N Shane Cutler; Ramona Graves-Deal; Bonnie J LaFleur; Zhenqiang Gao; Bruce M Boman; Robert H Whitehead; Erin Terry; Jason D Morrow; Robert J Coffey
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

6.  Clinical significance of angiogenesis in rectal carcinoid tumors.

Authors:  Seiji Onogawa; Shinji Tanaka; Shiro Oka; Masao Morihara; Yasuhiko Kitadai; Masaharu Sumii; Masaharu Yoshihara; Fumio Shimamoto; Ken Haruma; Kazuaki Chayama
Journal:  Oncol Rep       Date:  2002 May-Jun       Impact factor: 3.906

7.  Prognostic significance of immunohistochemically detected blood and lymphatic vessel invasion in colorectal carcinoma: its impact on prognosis.

Authors:  Pin Liang; Ichiro Nakada; Jian-Wei Hong; Takanobu Tabuchi; Gyo Motohashi; Akira Takemura; Takeshi Nakachi; Teruhiko Kasuga; Takafumi Tabuchi
Journal:  Ann Surg Oncol       Date:  2006-11-14       Impact factor: 5.344

8.  Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643.

Authors:  J M Peters; R C Cattley; F J Gonzalez
Journal:  Carcinogenesis       Date:  1997-11       Impact factor: 4.944

9.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors.

Authors:  S A Kliewer; B M Forman; B Blumberg; E S Ong; U Borgmeyer; D J Mangelsdorf; K Umesono; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

10.  Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations.

Authors:  P Bossi; G Viale; A K Lee; R Alfano; G Coggi; S Bosari
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701

View more
  13 in total

1.  Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-δ/β overexpression.

Authors:  Xiangsheng Zuo; Min Xu; Jiang Yu; Yuanqing Wu; Micheline J Moussalli; Ganiraju C Manyam; Sun Il Lee; Shoudan Liang; Mihai Gagea; Jeffrey S Morris; Russell R Broaddus; Imad Shureiqi
Journal:  J Natl Cancer Inst       Date:  2014-03-28       Impact factor: 13.506

Review 2.  The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.

Authors:  Jeffrey M Peters; Yatrik M Shah; Frank J Gonzalez
Journal:  Nat Rev Cancer       Date:  2012-02-09       Impact factor: 60.716

3.  The prognostic significance of peroxisome proliferator-activated receptor β expression in the vascular endothelial cells of colorectal cancer.

Authors:  Jin Zhou; Lie Yang; Yuan Li; Gunnar Arbman; Ke-Ling Chen; Bin Zhou; Yong-Yang Yu; Cun Wang; Xian-Ming Mo; You Lu; Zong-Guang Zhou; Xiao-Feng Sun
Journal:  J Gastroenterol       Date:  2013-07-03       Impact factor: 7.527

Review 4.  Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.

Authors:  Nicole Wagner; Kay-Dietrich Wagner
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

Review 5.  Targeting peroxisome proliferator-activated receptor-β/δ in colon cancer: how to aim?

Authors:  Min Xu; Xiangsheng Zuo; Imad Shureiqi
Journal:  Biochem Pharmacol       Date:  2012-10-04       Impact factor: 5.858

6.  PPARδ induces estrogen receptor-positive mammary neoplasia through an inflammatory and metabolic phenotype linked to mTOR activation.

Authors:  Hongyan Yuan; Jin Lu; Junfeng Xiao; Geeta Upadhyay; Rachel Umans; Bhaskar Kallakury; Yuhzi Yin; Michael E Fant; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Res       Date:  2013-06-27       Impact factor: 12.701

7.  Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes.

Authors:  Cyrus V Desouza; Lindsey Rentschler; Vivian Fonseca
Journal:  Diabetes Metab Syndr Obes       Date:  2009-09-25       Impact factor: 3.168

8.  Induction of metastatic gastric cancer by peroxisome proliferator-activated receptorδ activation.

Authors:  Claire B Pollock; Olga Rodriguez; Philip L Martin; Chris Albanese; Xin Li; Levy Kopelovich; Robert I Glazer
Journal:  PPAR Res       Date:  2010-12-27       Impact factor: 4.964

9.  PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials.

Authors:  Joseph Vamecq; Jean-Marie Colet; Jean Jacques Vanden Eynde; Gilbert Briand; Nicole Porchet; Stéphane Rocchi
Journal:  PPAR Res       Date:  2012-05-08       Impact factor: 4.964

Review 10.  Integrative and systemic approaches for evaluating PPARβ/δ (PPARD) function.

Authors:  Greta M P Giordano Attianese; Béatrice Desvergne
Journal:  Nucl Recept Signal       Date:  2015-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.